NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ZEPBOUND (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPBOUND (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with weight-related complications. It works by activating G-protein-linked receptors to enhance glucose-dependent insulin secretion and reduce appetite. Administered as a subcutaneous injection, it represents a new pharmacological class for obesity treatment.
Growth12.8 years to LOE
ZEPBOUND is in rapid growth phase within a market dominated by its sister product MOUNJARO; expect expanding commercial and access teams as label indications broaden.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Tirzepatide for Treatment of CCCA
Started Sep 2026
20 enrolled
Central Centrifugal Cicatricial Alopecia (CCCA)
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Started Sep 2026
18 enrolled
Diabetes Mellitus, Type 1OverweightObesity
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Started Sep 2026
20 enrolled
Pouch, IlealPouches, IleoanalBowel Diseases, Inflammatory
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Started Sep 2026
150 enrolled
Obesity
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Started Aug 2026
60 enrolled
Idiopathic Intracranial Hypertension (IIH)
Worked on ZEPBOUND at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.